PROTAC c-Met degrader-3

PROTAC c-Met degrader-3 (Compound 22b) (0.03-1000 nM; 24 h) potently degrades c-Met in EBC-1 lung cancer cells, with a DC₅₀ of 0.59 nM, and the maximum degradation rate reaches 96.14% at 15.6 nM^[1].
PROTAC c-Met degrader-3 (15.6 nM; 3-72 h) induces time-dependent degradation of c-Met in EBC-1 lung cancer cells, with a maximum degradation rate of up to 93.13% after treatment at 15.6 nM for 72 h^[1].
PROTAC c-Met degrader-3 potently inhibits the proliferation of c-Met-sensitive EBC-1 and Hs746T cancer cells, with IC₅₀ values of 4 nM and 8 nM, respectively, while shows weak activity in c-Met-insensitive A549 and HCT116 cells^[1].
PROTAC c-Met degrader-3 (3.9-15.6 nM; 7 days) significantly inhibits colony formation of EBC-1 lung cancer cells after 7 days of treatment at concentrations of 3.9, 7.8 and 15.6 nM^[1].
PROTAC c-Met degrader-3 potently inhibits the proliferation of Tepotinib (HY-14721)-resistant MKN45 gastric cancer cells, with an IC₅₀ value of 10 nM^[1].
PROTAC c-Met degrader-3 (5-50 nM; 72 h) induces apoptosis in EBC-1 lung cancer cells, and mainly drives cells into the early apoptotic stage after treatment at 5, 15 or 50 nM for 72 h^[1].
PROTAC c-Met degrader-3 (5-50 nM; 24 h) upregulates the expression of cleaved PARP and cleaved caspase-3 in EBC-1 lung cancer cells in a dose-dependent manner after 24 h of treatment, indicating that it induces apoptosis via these pathway markers^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.